Published in Annu Rev Pharmacol Toxicol on January 01, 2014
Icam-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation. PLoS One (2014) 0.86
Targeting and therapeutic peptides in nanomedicine for atherosclerosis. Exp Biol Med (Maywood) (2016) 0.79
Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis. Adv Healthc Mater (2015) 0.78
Taking up the cudgels for the traditional reactive oxygen and nitrogen species detection assays and their use in the cardiovascular system. Redox Biol (2017) 0.75
Vascular-targeted nanocarriers: design considerations and strategies for successful treatment of atherosclerosis and other vascular diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
In vivo imaging of endothelial cell adhesion molecule expression after radiosurgery in an animal model of arteriovenous malformation. PLoS One (2017) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol (2007) 6.85
Role of target geometry in phagocytosis. Proc Natl Acad Sci U S A (2006) 6.62
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett (1990) 5.14
Evolving functions of endothelial cells in inflammation. Nat Rev Immunol (2007) 4.94
Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev (2001) 4.52
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol (2007) 4.02
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm (2009) 3.49
Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release (2012) 3.41
Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation (1997) 3.28
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther (2008) 2.69
Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem (1998) 2.66
Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci U S A (2011) 2.63
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci (2003) 2.34
Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev (2004) 2.10
Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum (2006) 1.98
A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat Nanotechnol (2009) 1.94
Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol (2005) 1.81
Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radic Biol Med (2010) 1.71
Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opin Drug Deliv (2005) 1.61
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol (2003) 1.54
A carbohydrate-antioxidant hybrid polymer reduces oxidative damage in spermatozoa and enhances fertility. Nat Chem Biol (2005) 1.52
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci U S A (2012) 1.52
Targeted adenovirus mediated inhibition of NF-κB-dependent inflammatory gene expression in endothelial cells in vitro and in vivo. J Control Release (2012) 1.45
Flow dynamics, binding and detachment of spherical carriers targeted to ICAM-1 on endothelial cells. Biorheology (2009) 1.32
Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J Control Release (2010) 1.27
PEGylated dendrimers with core functionality for biological applications. Bioconjug Chem (2008) 1.24
Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther (2007) 1.21
Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A (2010) 1.19
Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release (2012) 1.18
Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials (2007) 1.17
Antioxidant strategies in respiratory medicine. Treat Respir Med (2006) 1.15
Dendrimers as a scaffold for nitric oxide release. J Am Chem Soc (2006) 1.14
Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci U S A (1997) 1.14
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) (2010) 1.12
PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J (2010) 1.11
Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther (2009) 1.11
Targeted delivery of therapeutics to endothelium. Cell Tissue Res (2008) 1.10
The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano (2012) 1.08
Polymer nanocarriers protecting active enzyme cargo against proteolysis. J Control Release (2005) 1.08
Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles. Mol Pharm (2010) 1.07
The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials (2006) 1.07
Nanocarriers for vascular delivery of antioxidants. Nanomedicine (Lond) (2011) 1.06
Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release (2008) 1.06
Controlling ligand surface density optimizes nanoparticle binding to ICAM-1. J Pharm Sci (2010) 1.05
The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase. Biomaterials (2010) 1.04
Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano (2011) 1.03
Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. Curr Vasc Pharmacol (2005) 1.03
Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J Control Release (2010) 1.02
Acute and chronic shear stress differently regulate endothelial internalization of nanocarriers targeted to platelet-endothelial cell adhesion molecule-1. ACS Nano (2012) 1.02
Pluronic-modified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neurons. Free Radic Biol Med (2010) 1.01
Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. J Control Release (2011) 1.01
Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature. J Pharmacol Exp Ther (2002) 1.00
The Development of Novel Therapies for Rheumatoid Arthritis. Expert Opin Ther Pat (2008) 0.99
Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol (2009) 0.99
Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol Pharmacol (2007) 0.99
Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res (2007) 0.97
Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomedicine (2010) 0.97
Targeted modulation of reactive oxygen species in the vascular endothelium. J Control Release (2011) 0.97
Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv (2011) 0.96
Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules (2007) 0.95
Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis. Nanomedicine (Lond) (2010) 0.94
Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation. ACS Nano (2013) 0.94
Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents. Int J Pharm (2008) 0.93
Therapeutic uses of antioxidant liposomes. Mol Biotechnol (2004) 0.92
Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats. J Appl Physiol (1985) (1989) 0.91
Liposomal antioxidants provide prolonged protection against acute respiratory distress syndrome. Surgery (2000) 0.91
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer (2012) 0.90
Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. Int J Nanomedicine (2012) 0.89
Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam. Mol Pharm (2009) 0.89
Synthesis and characterization of poly(ethylene glycol)-glutathione conjugate self-assembled nanoparticles for antioxidant delivery. Biomacromolecules (2009) 0.88
Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J Control Release (2010) 0.88
Delivery of antioxidant enzyme proteins to the lung. Antioxid Redox Signal (2001) 0.87
Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochim Biophys Acta (2002) 0.87
Drug incorporation and release of water soluble drugs from novel functionalized poly(glycerol adipate) nanoparticles. J Control Release (2007) 0.86
Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: in vitro effects on isolated neonatal porcine pancreatic cell clusters. J Control Release (2005) 0.86
Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells. Mol Pharm (2009) 0.86
Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J Control Release (2011) 0.86
Targeted transfection increases siRNA uptake and gene silencing of primary endothelial cells in vitro--a quantitative study. J Control Release (2009) 0.85
Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J Pharmacol Exp Ther (2007) 0.84
Tailor-made biofunctionalized nanoparticles using layer-by-layer technology. Int J Pharm (2010) 0.84
Imaging sites of infection using a 99mTc-labeled folate conjugate targeted to folate receptor positive macrophages. Mol Pharm (2012) 0.84
Poly(trimethylene carbonate) and monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate) nanoparticles for the controlled release of dexamethasone. J Control Release (2006) 0.83
Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J Pharmacol Exp Ther (2009) 0.83
Development and evaluation of emulsion-liposome blends for resveratrol delivery. J Nanosci Nanotechnol (2006) 0.83
Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res Ther (2009) 0.83
Introduction of short interfering RNA to silence endogenous E-selectin in vascular endothelium leads to successful inhibition of leukocyte adhesion. Biochem Biophys Res Commun (2003) 0.83
Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release. AAPS J (2009) 0.82
Liposome-encapsulated dexamethasone attenuates ventilator-induced lung inflammation. Br J Pharmacol (2011) 0.82
Reduced ischemia/reperfusion injury via glutathione-initiated nitric oxide-releasing dendrimers. Nitric Oxide (2009) 0.82
A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: sustained vascular response. Nitric Oxide (2012) 0.81
Liposome-entrapped antioxidant enzymes prevent lethal O2 toxicity in the newborn rat. J Appl Physiol (1985) (1987) 0.81
Prophylaxis against lipopolysaccharide-induced lung injuries by liposome-entrapped dexamethasone in rats. Biochem Pharmacol (2000) 0.81
Enzymosomes with surface-exposed superoxide dismutase: in vivo behaviour and therapeutic activity in a model of adjuvant arthritis. J Control Release (2006) 0.81
Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis. Rheumatol Int (1987) 0.80
Polymer micelles with hydrazone-ester dual linkers for tunable release of dexamethasone. Pharm Res (2011) 0.80
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther (2008) 2.69
A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci (2003) 2.34
Prostanoids in health and disease. J Lipid Res (2008) 2.06
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J Pharmacol Exp Ther (2006) 1.93
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol (2005) 1.81
PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress. Am J Physiol Lung Cell Mol Physiol (2003) 1.74
ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood (2004) 1.58
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol (2003) 1.54
Advanced drug delivery systems that target the vascular endothelium. Mol Interv (2006) 1.54
Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proc Natl Acad Sci U S A (2010) 1.53
Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol (2003) 1.46
Bioinformatic analysis of circadian gene oscillation in mouse aorta. Circulation (2005) 1.40
EBP, a program for protein identification using multiple tandem mass spectrometry datasets. Mol Cell Proteomics (2006) 1.36
Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood (2002) 1.30
In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J Nucl Med (2007) 1.30
Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther (2005) 1.29
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology (2006) 1.27
Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies. Biomaterials (2007) 1.17
Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther (2004) 1.16
Prostaglandin E synthases in zebrafish. Arterioscler Thromb Vasc Biol (2004) 1.16
Antioxidant strategies in respiratory medicine. Treat Respir Med (2006) 1.15
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 1.14
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood (2007) 1.14
Polymeric carriers: role of geometry in drug delivery. Expert Opin Drug Deliv (2008) 1.14
Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol (2006) 1.13
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood (2006) 1.11
Targeted detoxification of selected reactive oxygen species in the vascular endothelium. J Pharmacol Exp Ther (2009) 1.11
Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/bl6 mouse. Radiother Oncol (2006) 1.11
PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J (2010) 1.11
Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide. J Pharmacol Exp Ther (2007) 1.10
Analysis of the zebrafish proteome during embryonic development. Mol Cell Proteomics (2008) 1.09
Polymer nanocarriers protecting active enzyme cargo against proteolysis. J Control Release (2005) 1.08
Catalase and superoxide dismutase conjugated with platelet-endothelial cell adhesion molecule antibody distinctly alleviate abnormal endothelial permeability caused by exogenous reactive oxygen species and vascular endothelial growth factor. J Pharmacol Exp Ther (2011) 1.07
Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release (2008) 1.06
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther (2009) 1.05
Deciphering the human platelet sheddome. Blood (2010) 1.04
PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenet Genomics (2011) 1.03
Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano (2011) 1.03
The post-synaptic density of human postmortem brain tissues: an experimental study paradigm for neuropsychiatric illnesses. PLoS One (2009) 1.03
The shape of things to come: importance of design in nanotechnology for drug delivery. Ther Deliv (2012) 1.03
Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med (2009) 1.03
Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J Control Release (2010) 1.02
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab (2009) 1.02
Acute and chronic shear stress differently regulate endothelial internalization of nanocarriers targeted to platelet-endothelial cell adhesion molecule-1. ACS Nano (2012) 1.02
Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem (2007) 1.01
Induction of endothelial cell apoptosis by lipid hydroperoxide-derived bifunctional electrophiles. Free Radic Biol Med (2005) 1.01
Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. J Control Release (2011) 1.01
The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition. J Pharmacol Exp Ther (2007) 1.00
Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature. J Pharmacol Exp Ther (2002) 1.00
The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program (2005) 0.99
Collaborative enhancement of antibody binding to distinct PECAM-1 epitopes modulates endothelial targeting. PLoS One (2012) 0.98
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders. J Neurochem (2010) 0.98
Streptavidin-biotin crosslinking of therapeutic enzymes with carrier antibodies: nanoconjugates for protection against endothelial oxidative stress. Methods Mol Biol (2004) 0.98
Targeted modulation of reactive oxygen species in the vascular endothelium. J Control Release (2011) 0.97
COX-2, the dominant source of prostacyclin. Proc Natl Acad Sci U S A (2013) 0.96
Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules (2007) 0.95
Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirin. Clin Chem (2013) 0.95
Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J Pharmacol Exp Ther (2005) 0.94
Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo. J Control Release (2012) 0.94
Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury. J Neurotrauma (2009) 0.93
Advanced drug delivery systems for antithrombotic agents. Blood (2013) 0.92
Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano (2014) 0.92
Characterization of endothelial internalization and targeting of antibody-enzyme conjugates in cell cultures and in laboratory animals. Methods Mol Biol (2004) 0.91
PECAM-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide. Free Radic Biol Med (2003) 0.90
A neuroinductive biomaterial based on dopamine. Proc Natl Acad Sci U S A (2006) 0.90
Targeted Nanocarriers for Imaging and Therapy of Vascular Inflammation. Curr Opin Colloid Interface Sci (2011) 0.90
Endothelial targeting of polymeric nanoparticles stably labeled with the PET imaging radioisotope iodine-124. Biomaterials (2012) 0.89
Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J Control Release (2010) 0.88
Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. J Control Release (2009) 0.88
Loading PEG-catalase into filamentous and spherical polymer nanocarriers. Pharm Res (2008) 0.87
Targeted interception of signaling reactive oxygen species in the vascular endothelium. Ther Deliv (2012) 0.87
Anti-inflammatory effect of targeted delivery of SOD to endothelium: mechanism, synergism with NO donors and protective effects in vitro and in vivo. PLoS One (2013) 0.87
Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium. J Control Release (2007) 0.87
Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan. Exp Neurol (2011) 0.86
Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death. Transplantation (2011) 0.86
Filamentous polymer nanocarriers of tunable stiffness that encapsulate the therapeutic enzyme catalase. Biomacromolecules (2009) 0.85
Synthetic carriers for vascular delivery of protein therapeutics. Biotechnol Genet Eng Rev (2006) 0.85
Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2012) 0.84
Prostanoids and inflammatory pain. Prostaglandins Other Lipid Mediat (2012) 0.84
Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting. Thromb Haemost (2007) 0.84
Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema. J Pharmacol Exp Ther (2007) 0.84
Targeting antioxidant and antithrombotic biotherapeutics to endothelium. Semin Thromb Hemost (2010) 0.83
Apolipoprotein E activates Akt pathway in neuro-2a in an isoform-specific manner. Biochem Biophys Res Commun (2002) 0.83